selected publications
-
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
The Lancet. Oncology.
2020
Academic Article
GET IT
Times cited: 262 -
Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer.
The oncologist.
2019
Academic Article
GET IT
Times cited: 11 -
Comment on "Microsatellite Instability as a Predictive Biomarker for Adjuvant Chemotherapy in Gastric Cancer": Are we There Yet?.
Annals of surgery.
2019
Article
GET IT
Times cited: 2 -
Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2019
Academic Article
GET IT
Times cited: 13 -
EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.
Cancer discovery.
2018
Academic Article
GET IT
Times cited: 122 -
Outcomes of Radiation-Associated Esophageal Squamous Cell Carcinoma: The MSKCC Experience.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract.
2018
Academic Article
GET IT
Times cited: 5 -
Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association.
2018
Academic Article
GET IT
Times cited: 14 -
Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
BMC cancer.
2018
Academic Article
GET IT
Times cited: 72 -
Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.
Cancer discovery.
2017
Academic Article
GET IT
Times cited: 285 -
The Current Status of Immunotherapies in Esophagogastric Cancer.
Surgical oncology clinics of North America.
2017
Information Resource
GET IT
Times cited: 2 -
Controversies and Consensus in Preoperative Therapy of Esophageal and Gastroesophageal Junction Cancers.
Surgical oncology clinics of North America.
2017
Information Resource
GET IT
Times cited: 1 -
Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma.
Journal of gastrointestinal oncology.
2016
Academic Article
GET IT
Times cited: 10 -
Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma.
Cancer.
2016
Academic Article
GET IT
Times cited: 28 -
Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma.
British journal of cancer.
2015
Academic Article
GET IT
Times cited: 16 -
Ex Vivo Lymphadenectomy During Gastrectomy for Adenocarcinoma Optimizes Lymph Node Yield.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract.
2015
Academic Article
GET IT
Times cited: 23 -
Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.
PloS one.
2015
Academic Article
GET IT
Times cited: 41 -
Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma.
Annals of surgical oncology.
2015
Academic Article
GET IT
Times cited: 24 -
Emerging mAbs for the treatment of esophagogastric cancer.
Expert opinion on emerging drugs.
2014
Information Resource
GET IT
Times cited: 1 -
Management of gastric cancer.
Current opinion in gastroenterology.
2014
Information Resource
GET IT
Times cited: 15 -
Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer.
American journal of clinical oncology.
2014
Academic Article
GET IT
Times cited: 7 -
Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers.
Annals of surgical oncology.
2013
Academic Article
GET IT
Times cited: 19 -
Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma.
Journal for immunotherapy of cancer.
2013
Academic Article
GET IT
Times cited: 35 -
Adjuvant (postoperative) therapy for esophageal cancer.
Thoracic surgery clinics.
2013
Information Resource
GET IT
Times cited: 13 -
Depression, cytokines, and pancreatic cancer.
Psycho-oncology.
2013
Academic Article
GET IT
Times cited: 78 -
Emerging tyrosine kinase inhibitors for esophageal cancer.
Expert opinion on emerging drugs.
2013
Information Resource
GET IT
Times cited: 11 -
Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012.
The Lancet. Oncology.
2012
Information Resource
GET IT
Times cited: 49 - Adjuvant therapy in esophagogastric adenocarcinoma: controversies and consensus. Gastrointestinal cancer research : GCR. 2012 Academic Article GET IT
-
Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer.
Cancer.
2011
Academic Article
GET IT
Times cited: 54 -
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2010
Academic Article
GET IT
Times cited: 390 -
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.
Cancer.
2010
Academic Article
GET IT
Times cited: 385 -
Esophagogastric cancer: targeted agents.
Cancer treatment reviews.
2010
Information Resource
GET IT
Times cited: 49 -
Role of neoadjuvant therapy for esophageal adenocarcinoma.
Surgical oncology clinics of North America.
2009
Information Resource
GET IT
Times cited: 11 -
Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma.
Cancer immunity.
2009
Academic Article
GET IT
Times cited: 80 -
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.
Cancer investigation.
2009
Academic Article
GET IT
Times cited: 1 -
Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses.
Cytotherapy.
2009
Academic Article
GET IT
Times cited: 33 -
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.
Proceedings of the National Academy of Sciences of the United States of America.
2008
Academic Article
GET IT
Times cited: 303 -
Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction.
Expert review of anticancer therapy.
2008
Information Resource
GET IT
Times cited: 2 -
Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer.
Cancer chemotherapy and pharmacology.
2008
Academic Article
GET IT
Times cited: 37 -
Esophageal cancer: adjuvant therapy.
Cancer journal (Sudbury, Mass.).
2007
Information Resource
GET IT
Times cited: 13 -
Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2007
Article
GET IT
Times cited: 16